Boston Children's launches Phase I clinical trial of long-lasting local anesthetic derived from cyanobacteria

Boston Children's Hospital has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for neosaxitoxin, a new local anesthetic derived from cyanobacteria being developed in partnership with Proteus SA, of Santiago, Chile. With the IND approval in hand, the hospital has launched a Phase I clinical study in healthy volunteers...
Pain / Anesthetics News From Medical News Today

Related Content